The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients (pts) with chronic myeloid leukemia (CML).
M. Ulcickas Yood
Research Funding - Bristol-Myers Squibb
S. A. Oliveria
Research Funding - Bristol-Myers Squibb
I. Hirji
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
S. Phillips
Research Funding - Bristol-Myers Squibb
M. J. Cziraky
Employment or Leadership Position - HealthCore
Research Funding - Bristol-Myers Squibb; Novartis
C. C. Davis
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb